FY2025 EPS Estimates for ChromaDex Boosted by Roth Capital

ChromaDex Co. (NASDAQ:CDXC) – Roth Capital boosted their FY2025 earnings per share (EPS) estimates for ChromaDex in a research report issued to clients and investors on Wednesday, March 5th. Roth Capital analyst S. Mcgowan now expects that the company will post earnings per share of $0.07 for the year, up from their previous forecast of $0.05. The consensus estimate for ChromaDex’s current full-year earnings is $0.04 per share. Roth Capital also issued estimates for ChromaDex’s Q4 2025 earnings at $0.03 EPS, Q1 2026 earnings at $0.01 EPS, Q2 2026 earnings at $0.02 EPS, Q3 2026 earnings at $0.04 EPS, Q4 2026 earnings at $0.06 EPS and FY2027 earnings at $0.27 EPS.

Other equities analysts have also recently issued reports about the stock. LADENBURG THALM/SH SH upped their price objective on shares of ChromaDex from $6.80 to $8.10 and gave the stock a “buy” rating in a research report on Wednesday. StockNews.com lowered shares of ChromaDex from a “strong-buy” rating to a “buy” rating in a research note on Thursday.

ChromaDex Price Performance

ChromaDex stock opened at $7.69 on Thursday. The stock has a market capitalization of $587.39 million, a PE ratio of 769.77 and a beta of 2.21. The business has a 50 day simple moving average of $5.72 and a 200-day simple moving average of $5.15. ChromaDex has a 12 month low of $1.57 and a 12 month high of $9.18.

Insider Transactions at ChromaDex

In other news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the business’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $6.19, for a total transaction of $230,026.59. Following the transaction, the director now owns 244,179 shares of the company’s stock, valued at approximately $1,511,468.01. The trade was a 13.21 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 9.64% of the company’s stock.

Institutional Trading of ChromaDex

A number of hedge funds and other institutional investors have recently modified their holdings of the business. OneDigital Investment Advisors LLC grew its stake in shares of ChromaDex by 5.5% in the third quarter. OneDigital Investment Advisors LLC now owns 59,414 shares of the company’s stock valued at $217,000 after buying an additional 3,097 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in ChromaDex by 10.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 175,172 shares of the company’s stock valued at $639,000 after acquiring an additional 17,115 shares during the period. The Manufacturers Life Insurance Company grew its position in ChromaDex by 75.4% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 19,732 shares of the company’s stock valued at $72,000 after acquiring an additional 8,485 shares in the last quarter. Millrace Asset Group Inc. purchased a new stake in ChromaDex during the third quarter worth about $93,000. Finally, FMR LLC acquired a new stake in shares of ChromaDex during the third quarter worth about $55,000. 15.41% of the stock is owned by institutional investors and hedge funds.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.